Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2022

Open Access 01-12-2022 | Breast Disease | Review

The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis

Authors: Parisa Kohnepoushi, Hojat Dehghanbanadaki, Pardis Mohammadzedeh, Maziar Nikouei, Yousef Moradi

Published in: Cancer Cell International | Issue 1/2022

Login to get access

Abstract

This meta-analysis aimed to determine the pooled association between polycystic ovary syndrome (PCOS), hypothyroidism, and fibrocystic breast changes. We searched important databases, including PubMed (Medline), Scopus, Web of Science, and Embase to retrieve all relevant studies published from 1990 to April 2021. The bias risk of selected articles was assessed based on the JBI checklist. Our search strategy yielded a total of 487 articles from the international databases. After screening their full-texts, 6 articles met the inclusion criteria and were considered for meta-analysis. The effect of PCOS on the incidence of fibrocystic breast changes was 2.49 (95% CI 1.85–3.34). Also, the effect of hypothyroidism on the incidence of fibrocystic breast changes was 1.90 (95% CI 0.92–3.93). The results showed that women with PCOS were at higher risks to develop fibrocystic breast changes.
Literature
1.
Kahsar-Miller MD, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75(1):53–8.CrossRef
2.
Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467–520.CrossRef
3.
Dewailly D, et al. Polycystic ovary syndrome (PCOS). In: Annales D'endocrinologie. 2010. Elsevier.
4.
Kandaraki E, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011;96(3):E480–4.CrossRef
5.
Lizneva D, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.CrossRef
6.
Chen B, et al. The role of MiRNA in polycystic ovary syndrome (PCOS). Gene. 2019;706:91–6.CrossRef
7.
Dewailly D, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–9.CrossRef
8.
Liu M, Murthi S, Poretsky L. Focus: sex & reproduction: polycystic ovary syndrome and gender identity. Yale J Biol Med. 2020;93(4):529.PubMedPubMedCentral
9.
Dunaif A, Book CB. Insulin resistance in the polycystic ovary syndrome. Clin Res Diabetes Obes. 1997;15:249–74.CrossRef
10.
Zawadeski J, Dunaif A. Diagnostic criteria for PCOS: towards a more rational approach. PCOS. Boston: Blackwell Scientific; 1992. p. 377–84.
11.
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7.CrossRef
12.
Mohammad MB, Seghinsara AM. Polycystic ovary syndrome (PCOS), diagnostic criteria, and AMH. Asian Pac J Cancer Prev. 2017;18(1):17.PubMedCentral
13.
Azziz R, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab. 2006;91(11):4237–45.CrossRef
14.
Kunicki M, Smolarczyk R. Polycystic ovary syndrome and fibrocystic breast disease: an updated review. Horm Metab Res. 2021;53(4):219–24.CrossRef
15.
Chen Y-Y, et al. Examining the associations among fibrocystic breast change, total lean mass, and percent body fat. Sci Rep. 2018;8(1):1–6.
16.
Gungor ND, Gürbüz T, Okçu NT. Correlation between HbA1c and fibrocystic breast disease among polycystic ovary syndrome. Cumhuriyet Med J. 2020;4(3):383.
17.
Soran A, et al. The prevalence of benign breast disease in women with polycystic ovary syndrome: a review of a 12-year follow-up. Int J Clin Pract. 2005;59(7):795–7.CrossRef
18.
Gumus II, et al. Polycystic ovary syndrome and fibrocystic breast disease: is there any association? Arch Gynecol Obstet. 2009;280(2):249–53.CrossRef
19.
D’Amelio R, et al. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest. 2001;51(2):134–7.CrossRef
20.
Alipour S, Shirzad N, Saberi A, Seifollahi A, Rastad H, Hosseini L. Association of benign breast disorders with hypothyroidism. Istanbul Med J. 2018;19(3):246–50.CrossRef
21.
Anil C, Guney T, Gursoy A. The prevalence of benign breast diseases in patients with nodular goiter and Hashimoto’s thyroiditis. J Endocrinol Invest. 2015;38(9):971–5.CrossRef
22.
Tawfik GM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47(1):1–9.CrossRef
23.
Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRef
24.
Page MJ, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372.
25.
Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol. 1991;134(8):818–24.CrossRef
26.
Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: a meta-analysis. Obstet Gynecol Sci. 2016;59(5):367–72.CrossRef
27.
28.
Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2(1):1–9.CrossRef
29.
Kim J, et al. Polycystic ovarian syndrome (PCOS), related symptoms/sequelae, and breast cancer risk in a population-based case–control study. Cancer Causes Control. 2016;27(3):403–14.CrossRef
30.
Balen A. Polycystic ovary syndrome and cancer. Hum Reprod Update. 2001;7(6):522–5.CrossRef
31.
Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and breast cancer subtypes: a Mendelian randomization study. Am J Obstet Gynecol. 2021;225(1):99–101.CrossRef
32.
Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. J Clin Endocrinol Metab. 2021;107(3):e899–911.CrossRef
33.
Giani C, et al. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab. 1996;81(3):990–4.PubMed
34.
Leung AM, et al. Potential risks of excess iodine ingestion and exposure: statement by the American Thyroid Association Public Health Committee. Thyroid. 2015;25(2):145–6.CrossRef
35.
Bhargav PR, et al. Prevalence of hypothyroidism in benign breast disorders and effect of thyroxine replacement on the clinical outcome. World J Surg. 2009;33(10):2087–93.CrossRef
36.
Qureshi SF, Siddiqui JA, Shawosh YBA. Chlorpromazine-induced hyperprolactinemia in a young female and its relation with fibrocystic breast disease. J Mood Disord. 2016;6(4):230–3.CrossRef
37.
Rathlawath SK. Prevalence of hyperprolactinemia and hypothyroidism in benign breast disease in Government Rajaji Hospital, Madurai. Madurai Medical College: Madurai; 2017.
38.
Artene SD, Bordea CI, Mircea D, Blidaru A. Beetroot and carrot juice increase the risk of thyroid nodules and hypothyroidism in breast cancer patients. Rom J Med Pract. 2016;11(3):251–6.CrossRef
39.
Falstie-Jensen AM, et al. Incidence of hypothyroidism after treatment for breast cancer—a Danish matched cohort study. Breast Cancer Res. 2020;22(1):1–10.CrossRef
40.
Kuijpens JL, et al. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005;15(11):1253–9.CrossRef
Metadata
Title
The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis
Authors
Parisa Kohnepoushi
Hojat Dehghanbanadaki
Pardis Mohammadzedeh
Maziar Nikouei
Yousef Moradi
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2022
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-022-02547-5

Other articles of this Issue 1/2022

Cancer Cell International 1/2022 Go to the issue

Retraction Note

Retraction Note: LncRNA TUBA4B functions as a competitive endogenous RNA to inhibit gastric cancer progression by elevating PTEN via sponging miR-214 and miR-216a/b

Primary research

LncRNA TP73‐AS1 promotes nasopharyngeal carcinoma progression through targeting miR-342-3p and M2 polarization via exosomes

Primary research

Development of a prognostic pyroptosis-related gene signature for head and neck squamous cell carcinoma patient

Review

Intercellular crosstalk between cancer cells and cancer-associated fibroblasts via extracellular vesicles

Review

Notch-associated lncRNAs profiling circuiting epigenetic modification in colorectal cancer

Primary research

The regulation of autophagy by the miR-199a-5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits